For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

SLU-PP-332: origin, structure and research history

Research Library › Mitochondrial & Coenzyme

SLU-PP-332 is a synthetic small-molecule compound, not a peptide, designed to activate all three estrogen-related receptors (ERRα, ERRβ and ERRγ). It was reported in 2023 by Thomas Burris, Cyrielle Billon and colleagues from Washington University in St. Louis and Saint Louis University, whose initials give the compound its prefix. As of October 2026 it is an investigational research compound in preclinical study only, with no FDA approval and no registered human trial.

Key facts

TypeSynthetic small molecule (an aryl hydrazone); not a peptide
Chemical name(E)-4-hydroxy-N′-(naphthalen-2-ylmethylene)benzohydrazide; C18H14N2O2
First described2023, ACS Chemical Biology (named in a 2022 preprint)
Developed byThomas P. Burris, Cyrielle Billon, John K. Walker, Bahaa Elgendy and colleagues, Washington University in St. Louis and Saint Louis University
Designed targetEstrogen-related receptors ERRα, ERRβ and ERRγ (pan-agonist, highest reported potency at ERRα)
Regulatory status (Oct 2026)Not FDA-approved; preclinical only; no registered human trial; not named individually on the 2026 WADA Prohibited List

Who developed it

SLU-PP-332 was developed by a team built around nuclear-receptor pharmacologist Thomas P. Burris, working with first author Cyrielle Billon at Washington University School of Medicine in St. Louis and with medicinal chemists including John K. Walker at Saint Louis University School of Medicine. Collaborators at the Salk Institute, including Ronald Evans and Michael Downes, and at Baylor College of Medicine and City of Hope contributed to the first full paper, published in ACS Chemical Biology in 2023 [1].

The “SLU” prefix refers to Saint Louis University. Later papers from the same network included further work by the Burris and Walker groups and a study led by Lilei Zhang’s group at Baylor College of Medicine [2, 3].

Structure and design

Unlike most compounds in peptide research catalogs, SLU-PP-332 is not a peptide. It is a small organic molecule of 18 carbon atoms, chemically an aryl hydrazone joining a 4-hydroxybenzoyl group to a naphthalene ring through a hydrazone link (C18H14N2O2) [1, 4].

Its intended targets are the estrogen-related receptors, a trio of nuclear receptors first identified in 1988 by their sequence similarity to the estrogen receptor [5]. Despite the name, ERRs do not bind estrogen; they are “orphan” receptors with no confirmed natural hormone. Earlier synthetic ligands could activate ERRβ and ERRγ, but compounds that activate ERRα had proven hard to find. The 2023 paper described SLU-PP-332 as a pan-agonist that acts on all three ERRs, with its highest potency at ERRα in cell-based assays [1]. ERRs regulate genes involved in mitochondrial and energy metabolism, which is why the compound appears in the mitochondrial research literature.

Research history

All published work on SLU-PP-332 is preclinical: receptor assays, cultured cells and rodent studies. Researchers have also used it as a starting point for related molecules, such as SLU-PP-915, which has a different chemical scaffold [3].

  • 2022: Compound named in a bioRxiv preprint from the Baylor and Burris groups [3]
  • 2023: First full peer-reviewed description as an ERRα/β/γ agonist [1]
  • 2024: Further rodent studies in J Pharmacol Exp Ther and Circulation [2, 3]
  • 2026: An anti-doping laboratory publishes metabolism and detection studies of SLU-PP-332 [6, 7]

Regulatory status as of October 2026

SLU-PP-332 is not approved as a drug by the US Food and Drug Administration or any other regulator, and no human clinical trial of it has been registered or published. It remains a preclinical research compound.

It is not named individually on the 2026 WADA Prohibited List, which places pharmacological substances not approved for human use under section S0 [8]. In 2026 the WADA-accredited laboratory at the German Sport University Cologne published in vitro metabolism data on SLU-PP-332 for doping-control purposes [6, 7].

About this reference page

Kalibra Labs does not currently supply SLU-PP-332. This page is published as a neutral scientific and regulatory reference. Browse the Mitochondrial & Coenzyme guide or the FDA Peptide Regulatory Tracker.

Frequently asked questions

Is SLU-PP-332 a peptide?

No. SLU-PP-332 is a synthetic small molecule (an aryl hydrazone, C18H14N2O2), not a chain of amino acids [1, 4].

Who developed SLU-PP-332?

It was developed by Thomas Burris, Cyrielle Billon and colleagues at Washington University in St. Louis and Saint Louis University, and first fully described in 2023 [1].

What does SLU-PP-332 target?

It was designed to activate the estrogen-related receptors ERRα, ERRβ and ERRγ, with its highest reported potency at ERRα in cell assays [1].

Is SLU-PP-332 FDA approved?

No. As of October 2026 it is not FDA-approved, has no registered human trial, and all published research is preclinical.

Sources

  1. Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, et al., Walker JK, Downes M, Evans RM, Burris TP. Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity. ACS Chem Biol. 2023;18(4):756–771. doi:10.1021/acschembio.2c00720. Link
  2. Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP. A synthetic ERR agonist alleviates metabolic syndrome. J Pharmacol Exp Ther. 2024;388(2):232–240. doi:10.1124/jpet.123.001733. Link
  3. Xu W, Billon C, Li H, et al., Walker JK, Burris T, Zhang L. Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function. Circulation. 2024;149(3):227–250. doi:10.1161/CIRCULATIONAHA.123.066542. Preprint: bioRxiv 2022, doi:10.1101/2022.02.14.480431. Link
  4. Patsnap Synapse. SLU-PP-332 drug record: small molecule, ERR agonist, CAS 303760-60-3, C18H14N2O2; highest phase preclinical (updated 20 Oct 2025). Link
  5. Giguère V, Yang N, Segui P, Evans RM. Identification of a new class of steroid hormone receptors. Nature. 1988;331(6151):91–94. doi:10.1038/331091a0. Link
  6. Möller T, Krug O, Thevis M. In vitro metabolism and analytical characterization of SLU-PP-332 and SLU-PP-915: novel pan-ERR agonists with doping potential. Rapid Commun Mass Spectrom. 2026. PMID 41588687. Link
  7. German Sport University Cologne, Institute of Biochemistry. Doping glossary: SLU-PP-332 and SLU-PP-915, estrogen-related receptor (ERR) agonists. Link
  8. World Anti-Doping Agency. 2026 Prohibited List. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top